ARGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Argenx SE (ARGX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock demonstrates strong financial growth, positive analyst sentiment, and bullish technical indicators. Despite the absence of recent news or significant insider/hedge fund activity, the company's robust revenue and earnings growth, along with its promising pipeline and commercial execution, make it a compelling long-term investment.
The technical indicators for ARGX are bullish. The MACD is positive and expanding, the RSI is neutral at 62.344, and moving averages are in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 834.801, with resistance levels at 854.277 and 866.309, suggesting potential upward movement.
Strong financial performance in Q3 2025, with revenue up 96.60% YoY and net income up 276.61% YoY. EPS also increased significantly by 272.66% YoY.
Positive analyst sentiment, with multiple firms raising price targets and maintaining Buy or Overweight ratings.
The company's Vyvgart launch continues to gain momentum, with analysts projecting significant growth in sales.
Bullish technical indicators and a strong growth trajectory.
One analyst downgraded the stock to Neutral, citing valuation concerns.
No recent news or significant insider/hedge fund activity to act as immediate catalysts.
High expectations may already be priced into the stock, as noted by some analysts.
In Q3 2025, Argenx reported outstanding financial performance. Revenue increased by 96.60% YoY to $1.13 billion, net income rose by 276.61% YoY to $344.26 million, and EPS surged by 272.66% YoY to 5.18. Gross margin also improved slightly to 90.29%. These results highlight strong growth and profitability.
Analysts are overwhelmingly positive on ARGX, with multiple firms raising price targets recently. Wells Fargo raised its target to $1,317, Morgan Stanley to $1,160, and Truist to $1,030, all maintaining Buy or Overweight ratings. Analysts highlight strong growth potential for Vyvgart and the company's robust pipeline. However, one analyst downgraded the stock to Neutral, citing stretched valuation.
